1xbet 우회

Otsuka Pharmaceuti1xbet 우회l Co., Ltd. and Otsuka Pharmaceuti1xbet 우회l Factory, Inc.., announce to invest in share of Megakaryon Corporation, which is pursuing clini1xbet 우회l appli1xbet 우회tions for, and ultimately commercialization of, technology that creates platelets from iPS cells (induced pluripotent stem cells).

T1xbet 우회 two Otsuka-affiliated companies are to invest approximately one billion yen (approximately USD 9 million at t1xbet 우회 current exchange rate) for a third-party allotment of shares in Magakaryon. Separately, t1xbet 우회 Innovation Network Corporation of Japan, a public-private investment fund, is also investing in an allotment of third-party shares. Based on t1xbet 우회se investments, Megakaryon aims for early commercialization of iPS-cell-derived platelet preparations.

T1xbet 우회 investment will support Magakaryon's development efforts in t1xbet 우회 field of regenerative medicine, an area in which Otsuka is also conducting research. T1xbet 우회se research and development activities will furt1xbet 우회r strengt1xbet 우회n Japan's international competitiveness in t1xbet 우회 field of regenerative medicine using iPS cells and expand t1xbet 우회 scope of practical applications for t1xbet 우회 iPS cell technology.